P2 Capital Partners LLC Sells 22,149 Shares of Enovis Corporation $ENOV

P2 Capital Partners LLC trimmed its stake in shares of Enovis Corporation (NYSE:ENOV) by 3.6% during the third quarter, HoldingsChannel reports. The fund owned 595,000 shares of the company’s stock after selling 22,149 shares during the period. Enovis comprises about 3.5% of P2 Capital Partners LLC’s investment portfolio, making the stock its 11th largest position. P2 Capital Partners LLC’s holdings in Enovis were worth $18,052,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. Comerica Bank boosted its stake in Enovis by 3.4% in the 3rd quarter. Comerica Bank now owns 52,119 shares of the company’s stock worth $1,581,000 after purchasing an additional 1,735 shares during the period. Brown Brothers Harriman & Co. acquired a new stake in shares of Enovis in the 3rd quarter valued at about $90,000. Entropy Technologies LP raised its stake in shares of Enovis by 92.4% in the 3rd quarter. Entropy Technologies LP now owns 18,346 shares of the company’s stock valued at $557,000 after purchasing an additional 8,812 shares during the period. Landscape Capital Management L.L.C. bought a new stake in shares of Enovis in the third quarter valued at about $400,000. Finally, Kennedy Capital Management LLC lifted its holdings in shares of Enovis by 2.0% in the third quarter. Kennedy Capital Management LLC now owns 173,119 shares of the company’s stock valued at $5,252,000 after purchasing an additional 3,426 shares in the last quarter. 98.45% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider Oliver Engert purchased 1,000 shares of the stock in a transaction on Friday, February 27th. The shares were purchased at an average price of $25.50 per share, with a total value of $25,500.00. Following the transaction, the insider directly owned 43,640 shares of the company’s stock, valued at $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders purchased 4,000 shares of company stock valued at $98,243 in the last ninety days. 2.70% of the stock is owned by company insiders.

Enovis Trading Down 1.7%

Enovis stock opened at $22.99 on Friday. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -1.11 and a beta of 1.46. The firm has a 50-day moving average of $23.81 and a 200-day moving average of $27.82. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04. Enovis Corporation has a one year low of $21.00 and a one year high of $40.69.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The business had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. During the same quarter in the previous year, the business earned $0.98 earnings per share. Enovis’s quarterly revenue was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts expect that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on ENOV. UBS Group reiterated a “buy” rating and set a $50.00 price objective on shares of Enovis in a report on Monday, January 5th. Evercore restated an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Canaccord Genuity Group reduced their price target on Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. Needham & Company LLC raised their price target on shares of Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Finally, Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $47.43.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.